TROG 98.03 - Prostate - Margin +ve Post-Prostatectomy

By w.paterson
15 August, 2021
0 Comments

Randomised Trial to Compare the Rates of Disease-Free Survival in Margine-Positive Patients After Radical Prostatectomy With or Without Adjuvant Post-Operative Radiotherapy

Primary Sponsor

Trans-Tasman Radiation Oncology Group (TROG)

HeSANDA database for clinical trial data

21 April, 2025

Trial data-sharing made easier with HeSANDA initiative

Latest News: 21 April 2025 TROG Cancer Research is

16 April, 2025

Mark Hughes Foundation grant for innovative SMART trial into brain metastases

LATEST NEWS: 15 April 2025 An innovative trial aimed

For over 30 years, Trans-Tasman Radiation Oncology Group has been dedicated to improving the way radiation medicine is delivered to cancer patients with ongoing scientific research, clinical trials, and cutting-edge technology.

Quick Links

Legalities

Randomised Trial to Compare the Rates of Disease-Free Survival in Margine-Positive Patients After Radical Prostatectomy With or Without Adjuvant Post-Operative Radiotherapy

TROG 98.04 – Liver Metastases

TROG 98.02/EFC3344 – Head & Neck/Tirapazamine (Phase II)

Related Post

Trial data-sharing made easier with HeSANDA initiative

Mark Hughes Foundation grant for innovative SMART trial into brain metastases

TROG 98.03 – Prostate – Margin +ve Post-Prostatectomy

Randomised Trial to Compare the Rates of Disease-Free Survival in Margine-Positive Patients After Radical Prostatectomy With or Without Adjuvant Post-Operative Radiotherapy

TROG 98.04 – Liver Metastases

TROG 98.02/EFC3344 – Head & Neck/Tirapazamine (Phase II)

Related Post

Trial data-sharing made easier with HeSANDA initiative

Mark Hughes Foundation grant for innovative SMART trial into brain metastases